A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014-2022)
Background: The REFLECT phase-III trial has demonstrated the efficacy of lenvatinib in improving the overall survival of advanced hepatocellular carcinoma (HCC) patients, comparable to sorafenib. The rapidly evolving landscape of hepatocellular carcinoma therapy presents new avenues for lenvatinib....
Saved in:
Main Authors: | Cong-Cong Wang (Author), Cai-Yan Yu (Author), Jing Zhang (Author), Rui Wang (Author), Xiang-Shuo Kong (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lenvatinib for Hepatocellular Carcinoma: A Literature Review
by: Takeshi Hatanaka, et al.
Published: (2021) -
The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
by: Matthew Man Pok Lee, et al.
Published: (2023) -
Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy
by: Xiaomi Li, et al.
Published: (2023) -
Impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of lenvatinib in patients with hepatocellular carcinoma
by: Hironao Okubo, et al.
Published: (2022) -
circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma
by: Pengfei Zhang, et al.
Published: (2022)